Neurotransmitters as regulators of tumor angiogenesis and immunity: The role of catecholamines

Journal of Neuroimmune Pharmacology

Volumn 8, Issue 1, 2013, Pages 7-14

  Sarkar, Chandrani ^a   Chakroborty, Debanjan ^a   Basu, Sujit ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Angiogenesis; Catecholamine; Immunity; Tumor

Indexed keywords

ANGIOPOIETIN 1; CATECHOLAMINE; DOPAMINE; DOXORUBICIN; FLUOROURACIL; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROPRANOLOL; VASCULOTROPIN;

ADRENERGIC SYSTEM; BEHAVIORAL STRESS; CANCER GROWTH; CANCER IMMUNIZATION; CELL MIGRATION; CELL PROLIFERATION; CELLS; CYTOTOXIC LYMPHOCYTE; DEPRESSION; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG POTENTIATION; ENDOTHELIAL PROGENITOR CELL; ENDOTHELIUM CELL; HUMAN; KILLER CELL; LYMPHOCYTE; METASTASIS; MONOCYTE; NATURAL KILLER CELL; NEOVASCULARIZATION (PATHOLOGY); NEUROIMMUNOLOGY; NEUTROPHIL; NONHUMAN; OVARY CARCINOMA; PANCREAS CANCER; PERICYTE; PERITONEUM MACROPHAGE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR IMMUNITY; UPREGULATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CATECHOLAMINES; DOPAMINE; EPINEPHRINE; HUMANS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE;

EID: 84874649120     PISSN: 15571890     EISSN: 15571904     Source Type: Journal    
DOI: 10.1007/s11481-012-9395-7     Document Type: Review

References (109)

1. Alvarez C, Martí-Bonmatí L, Novella-Maestre E, Sanz R, Gómez R, Fernández-Sánchez M, Simón C, Pellicer A (2007) Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. J Clin Endocrinol Metab 92:2931-2937
2. Antoni MH, Lutgendorf SK, Cole SW, Dhabhar FS, Sephton SE, McDonald PG, Stefanek M, Sood AK (2006) The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer 6:240-248
3. Asada M, Ebihara S, Numachi Y, Okazaki T, Yamanda S, Ikeda K, Yasuda H, Sora I, Arai H (2008) Reduced tumor growth in a mouse model of schizophrenia, lacking the dopamine transporter. Int J Cancer 123:511-518
4. Asahara T, Masuda H, Takahashi T, Kalka C, Pastore C, Silver M, Kearne M, Magner M, Isner JM (1999) Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization. Circ Res 85:221-228
5. Axelsson J (1971) Catecholamine functions. Annu Rev Physiol 33:1-30
6. Baker JG, Hill SJ, Summers RJ (2011) Evolution of beta-blockers: from anti-anginal drugs to ligand-directed signalling. Trends Pharmacol Sci 32:227-234
7. Barnes NM, Gordon J (2008) Harnessing serotonergic and dopaminergic pathways for lymphoma therapy: evidence and aspirations. Semin Cancer Biol 18:218-225
8. Barron TI, Connolly RM, Sharp L, Bennett K, Visvanathan K (2011) Beta blockers and breast cancer mortality: a population- based study. J Clin Oncol 29:2635-2644
9. Barth E, Albuszies G, Baumgart K, Matejovic M, Wachter U, Vogt J, Radermacher P, Calzia E (2007) Glucose metabolism and catecholamines. Crit Care Med 35:S508-S518
10. Basu S, Dasgupta PS (2000a) Dopamine, a neurotransmitter, influences the immune system. J Neuroimmunol 102:113-124
11. Basu S, Dasgupta PS (2000b) Role of dopamine in malignant tumor growth. Endocrine 12:237-241
12. Basu S, Dasgupta PS, Ray MR, Lahiri T (1992a) Stimulation of NK activity in Ehrlich ascites carcinoma -bearing mice following dopamine treatment. Biogenic Amines 8:191-197
13. Basu S, Banerjee S, Dasgupta PS, Roy Chowdhury J (1992b) Stimulation of splenic lymphocyte proliferation and increased life span of solid Ehrlich carcinoma-bearing mice following dopamine treatment. Biogenic Amines 9:177-181
14. Basu S, Dasgupta PS, Lahiri T, Chowdhury JR (1993) Uptake and biodistribution of dopamine in bone marrow, spleen and lymph nodes of normal and tumor bearing mice. Life Sci 53:415-424
15. Basu S, Dasgupta PS, Roy Chowdhury J (1995a) Altered plasma level and uptake of dopamine by platelets in some human malignant tumors. Biogenic Amines 11:31-38
16. Basu S, Dasgupta PS, Chowdhury JR (1995b) Enhanced tumor growth in brain dopamine-depleted mice following 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment. J Neuroimmunol 60:1-8
17. Basu S, Nagy JA, Pal S, Vasile E, Eckelhoefer IA, Bliss VS, Manseau EJ, Dasgupta PS, Dvorak HF, Mukhopadhyay D (2001) The neurotransmitter dopamine inhibits angiogenesis induced by vascular permeability factor/vascular endothelial growth factor. Nat Med 7:569-574
18. Basu S, Sarkar C, Chakroborty D, Nagy J, Mitra RB, Dasgupta PS, Mukhopadhyay D (2004) Ablation of peripheral dopaminergic nerves stimulates malignant tumor growth by inducing vascular permeability factor/vascular endothelial growth factor-mediated angiogenesis. Cancer Res 64:5551-5555
19. Battegay EJ (1995) Angiogenesis: mechanistic insights, neovascular diseases, and therapeutic prospects. J Mol Med (Berl) 73:333-346
20. Ben-Eliyahu S, Shakhar G, Page GG, Stefanski V, Shakhar K (2000) Suppression of NK cell activity and of resistance to metastasis by stress: a role for adrenal catecholamines and beta-adrenoceptors. Neuroimmunomodulation 8:154-164
21. Ben-Jonathan N (1985) Dopamine: a prolactin-inhibiting hormone. Endocr Rev 6:564-589
22. Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer 3:401-410
23. Bergquist J, Tarkowski A, Ekman R, Ewing A (1994) Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci U S A 91:12912-12916
24. Beyer M, Schultze JL (2006) Regulatory T cells in cancer. Blood 108:804-811
25. Botta F, Maestroni GJ (2008) Adrenergic modulation of dendritic cell cancer vaccine in a mouse model: role of dendritic cell maturation. J Immunother 31:263-270
26. Bushe CJ, Hodgson R (2010) Schizophrenia and cancer: in 2010 do we understand the connection? Can J Psychiatry 55:761-767
27. Chakroborty D, Sarkar C, Mitra RB, Banerjee S, Dasgupta PS, Basu S (2004) Depleted dopamine in gastric cancer tissues: dopamine treatment retards growth of gastric cancer by inhibiting angiogenesis. Clin Cancer Res 10:4349-4356
28. Chakroborty D, Chowdhury UR, Sarkar C, Baral R, Dasgupta PS, Basu S (2008) Dopamine regulates endothelial progenitor cell mobilization from mouse bone marrow in tumor vascularization. J Clin Invest 118:1380-1389
29. Chakroborty D, Sarkar C, Basu B, Dasgupta PS, Basu S (2009) Catecholamines regulate tumor angiogenesis. Cancer Res 69:3727-3730
30. Chakroborty D, Sarkar C, Yu H, Wang J, Liu Z, Dasgupta PS, Basu S (2011) Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Kruppel-like factor-2 expression in tumor endothelial cells. Proc Natl Acad Sci U S A 108:20730-20735
31. Chambers DA, Cohen RL, Perlman RL (1993) Neuroimmune modulation: signal transduction and catecholamines. Neurochem Int 22:95-110
32. Cole SW, Sood AK (2012) Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res 18:1201-1206
33. Coronella JA, Telleman P, Kingsbury GA, Truong TD, Hays S, Junghans RP (2001) Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. Cancer Res 61:7889-7899
34. Cosentino M, Fietta AM, Ferrari M, Rasini E, Bombelli R, Carcano E, Saporiti F, Meloni F, Marino F, Lecchini S (2007) Human CD4+CD25+ regulatory T cells selectively express tyrosine hydroxylase and contain endogenous catecholamines subserving an autocrine/paracrine inhibitory functional loop. Blood 109:632-642
35. Daly CJ, McGrath JC (2011) Previously unsuspected widespread cellular and tissue distribution of beta-adrenoceptors and its relevance to drug action. Trends Pharmacol Sci 32:219-226
36. Dasgupta PS, Lahiri T (1987) Stimulation of tumoricidal activity of peritoneal macrophage by dopamine treatment. Med Sci Res 15:1301-1302
37. Dvorak HF (2005) Angiogenesis: update 2005. J Thromb Haemost 3:1835-1842
38. Eisenhofer G, Aneman A, Hooper D, Rundqvist B, Friberg (1996) Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humans. J Neurochem 66:1565-1573
39. Eisenhofer G, Aneman A, Friberg P, Hooper D, Fåndriks L, Lonroth H, Hunyady B, Mezey E (1997) Substantial production of dopamine in the human gastrointestinal tract. J Clin Endocrinol Metab 82:3864-3871
40. Elenkov IJ, Wilder RL, Chrousos GP, Vizi ES (2000) The sympathetic nerve-an integrative interface between two supersystems: the brain and the immune system. Pharmacol Rev 52:595-638
41. Ferrari M, Cosentino M, Marino F, Bombelli R, Rasini E, Lecchini S, Frigo G (2004) Dopaminergic D1-like receptor-dependent inhibition of tyrosine hydroxylase mRNA expression and catecholamine production in human lymphocytes. Biochem Pharmacol 67:865-873
42. Folkman J (2007) Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 6:273-286
43. Ganong WF (2005) Synaptic and junctional transmission. In: Ganong WF (ed) Review of medical physiology. McGraw-Hill, New York, pp 85-120
44. Ganong WF, Alper RH, Steels MK (1985) In: Jonathon NB, Bahrs JM, Weiners RI (eds) Catecholamines as hormone regulator. Raven, New York, pp 13-18
45. Glaser R, Kiecolt-Glaser JK (2005) Stress-induced immune dysfunction: implications for health. Nat Rev Immunol 5:243-251
46. Goldstein DS, Eisenhofer G, Kopin IJ (2003) Sources and significance of plasma levels of catechols and their metabolites in humans. J Pharmacol Exp Ther 305:800-811
47. Guo K, Ma Q, Wang L, Hu H, Li J, Zhang D, Zhang M (2009) Norepinephrine-induced invasion by pancreatic cancer cells is inhibited by propranolol. Oncol Rep 22:825-830
48. Hanahan D, Folkman J (1996) Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86:353-364
49. Havel RJ (1968) The autonomic nervous system and intermediary carbohydrate and fat metabolism. Anesthesiology 29:702-713
50. Herman JP, Prewitt CM, Cullinan WE (1996) Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Crit Rev Neurobiol 10:371-394
51. Hopkins A (2008) Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4:682-690
52. Inbar S, Neeman E, Avraham R, Benish M, Rosenne E, Ben-Eliyahu S (2011) Do stress responses promote leukemia progression? An animal study suggesting a role for epinephrine and prostaglandin-E2 through reduced NK activity. PLoS One 6:e19246
53. Jain RK (2005) Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307:58-62
54. Kamp T, Liebl B, Haen E, Emmerich B, Hallek M (1997) Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest 27:121-127
55. Kirillova GP, Hrutkay RJ, Shurin MR, Shurin GV, Tourkova IL, Vanyukov MM (2008) Dopamine receptors in human lymphocytes: radioligand binding and quantitative RT PCR assays. J Neurosci Methods 174:272-280
56. Laverty R (1978) Catecholamines: role in health and disease. Drugs 16:418-440
57. Lissoni P, Vaghi M, Pescia S, Rovelli F, Ardizzola A, Valtulina F, Malugani F, Gardani G, Tancini G (2004) Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia. J Biol Regul Homeost Agents 18:291-294
58. Lutgendorf SK, Lamkin DM, Jennings NB, Arevalo JM, Penedo F, DeGeest K, Langley RR, Lucci JA 3rd, Cole SW, Lubaroff DM, Sood AK (2008) Biobehavioral influences on matrix metalloproteinase expression in ovarian carcinoma. Clin Cancer Res 14:6839-6846
59. Lutgendorf SK, DeGeest K, Dahmoush L, Farley D, Penedo F, Bender D, Goodheart M, Buekers TE, Mendez L, Krueger G, Clevenger L, Lubaroff DM, Sood AK, Cole SW (2011) Social isolation is associated with elevated tumor norepinephrine in ovarian carcinoma patients. Brain Behav Immun 25:250-255
60. Lyman GH (1992) Risk factors for cancer. Prim Care 19:465-479
61. Mamani-Matsuda M, Moynet D, Molimard M, Ferry-Dumazet H, Marit G, Reiffers J, Mossalayi MD (2004) Long-acting beta2-adrenergic formoterol and salmeterol induce the apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol 124:141-150
62. Marino F, Cosentino M (2011) Adrenergic modulation of immune cells: an update. Amino Acids. doi: 10.1007/s00726-011-1186-6
63. Mayer SE (1974) Effect of catecholamines on cardiac metabolism. Circ Res 35:129-137
64. McEwen BS (2007) Physiology and neurobiology of stress and adaptation: central role of the brain. Physiol Rev 87:873-904
65. McKenna F, McLaughlin PJ, Lewis BJ, Sibbring GC, Cummerson JA, Bowen-Jones D, Moots RJ (2002) Dopamine receptor expression on human T-and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J Neuroimmunol 132:34-40
66. Melhem-Bertrandt A, Chavez-Macgregor M, Lei X, Brown EN, Lee RT, Meric-Bernstam F, Sood AK, Conzen SD, Hortobagyi GN, Gonzalez-Angulo AM (2011) Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol 29:2645-2652
67. Mignini F, Tomassoni D, Traini E, Amenta F (2009) Dopamine, vesicular transporters and dopamine receptor expression and localization in rat thymus and spleen. J Neuroimmunol 206:5-13
68. Missale C, Nash SR, Robinson SW, Jaber M, Caron MG (1998) Dopamine receptors: from structure to function. Physiol Rev 78:189-225
69. Moreno-Smith M, Lutgendorf SK, Sood AK (2010) Impact of stress on cancer metastasis. Future Oncol 6:1863-1881
70. Moreno-Smith M, Lu C, Shahzad MM, Pena GN, Allen JK, Stone RL, Mangala LS, Han HD, Kim HS, Farley D, Berestein GL, Cole SW, Lutgendorf SK, Sood A (2011) Dopamine blocks stress-mediated ovarian carcinoma growth. Clin Cancer Res 17:3649-3659
71. Nakano K, Higashi T, Hashimoto K, Takagi R, Tanaka Y, Matsushita S (2008) Antagonizing dopamine D1-like receptor inhibits Th17 cell differentiation: preventive and therapeutic effects on experimental autoimmune encephalomyelitis. Biochem Biophys Res Commun 373:286-291
72. Nakano K, Higashi T, Takagi R, Hashimoto K, Tanaka Y, Matsushita S (2009) Dopamine released by dendritic cells polarizes Th2 differentiation. Int Immunol 21:645-654
73. Nance DM, Sanders VM (2007) Autonomic innervation and regulation of the immune system (1987-2007). Brain Behav Immun 21:736-745
74. Nilsson MB, Armaiz-Pena G, Takahashi R, Lin YG, Trevino J, Li Y, Jennings N, Arevalo J, Lutgendorf SK, Gallick GE, Sanguino AM, Lopez-Berestein G, Cole SW, Sood AK (2007) Stress hormones regulate interleukin-6 expression by human ovarian carcinoma cells through a Src-dependent mechanism. J Biol Chem 282:29919-29926
75. Park SY, Kang JH, Jeong KJ, Lee J, Han JW, Choi WS, Kim YK, Kang J, Park CG, Lee HY (2011) Norepinephrine induces VEGF expression and angiogenesis by a hypoxia-inducible factor-1α protein-dependent mechanism. Int J Cancer 128:2306-2316
76. Pasquier E, Ciccolini J, Carre M, Giacometti S, Fanciullino R, Pouchy C, Montero MP, Serdjebi C, Kavallaris M, André N (2011) Propranolol potentiates the anti-angiogenic effects and anti-tumor efficacy of chemotherapy agents: implication in breast cancer treatment. Oncotarget 2:797-809
77. Perron L, Bairati I, Harel F, Meyer F (2004) Antihypertensive drug use and the risk of prostate cancer (Canada). Cancer Causes Control 15:535-541
78. Powe DG, Voss MJ, Zänker KS, Habashy HO, Green AR, Ellis IO, Entschladen F (2010) Beta-blocker drug therapy reduces secondary cancer formation in breast cancer and improves cancer specific survival. Oncotarget 7:628-638
79. Price MA, Tennant CC, Butow PN, Smith RC, Kennedy SJ, Kossoff MB, Dunn SM (2001) The role of psychosocial factors in the development of breast carcinoma: part II. Life event stressors, social support, defense style, and emotional control and their interactions. Cancer 91:686-697
80. Redelman D, Welniak LA, Taub D, Murphy WJ (2008) Neuroendocrine hormones such as growth hormone and prolactin are integral members of the immunological cytokine network. Cell Immunol 252:111-121
81. Reiche EM, Nunes SO, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5:617-625
82. Robison GA, Butcher RW, Sutherland EW (1967) Adenyl cyclase as an adrenergic receptor. Ann N Y Acad Sci 139:703-723
83. Rubí B, Maechler P (2010) Minireview: new roles for peripheral dopamine on metabolic control and tumor growth: let's seek the balance. Endocrinology 151:5570-5581
84. Sarkar C, Chakroborty D, Mitra RB, Banerjee S, Dasgupta PS, Basu S (2004) Dopamine in vivo inhibits VEGF-induced phosphorylation of VEGFR-2, MAPK, and focal adhesion kinase in endothelial cells. Am J Physiol Heart Circ Physiol 287:H1554-H1560
85. Sarkar C, Chakroborty D, Chowdhury UR, Dasgupta PS, Basu S (2008) Dopamine increases the efficacy of anticancer drugs in breast and colon cancer preclinical models. Clin Cancer Res 14:2502-2510
86. Sarkar C, Basu B, Chakroborty D, Dasgupta PS, Basu S (2010) The immunoregulatory role of dopamine: an update. Brain Behav Immun 24:525-528
87. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331:1565-1570
88. Schuller HM (2007) Neurotransmitter receptor-mediated signaling pathways as modulators of carcinogenesis. Prog Exp Tumor Res 39:45-63
89. Seeman P, Kapur S (2000) Schizophrenia: more dopamine, more D2 receptors. Proc Natl Acad Sci U S A 97:7673-7675
90. Shah SM, Carey IM, Owen CG, Harris T, Dewilde S, Cook DG (2011) Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. Br J Clin Pharmacol 72:157-161
91. Shahzad MM, Arevalo JM, Armaiz-Pena GN, Lu C, Stone RL, Moreno-Smith M, Nishimura M, Lee JW, Jennings NB, Bottsford-Miller J, Vivas-Mejia P, Lutgendorf SK, Lopez-Berestein G, Bar-Eli M, Cole SW, Sood AK (2010) Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem 285:35462-35470
92. Shakhar G, Ben-Eliyahu S (1998) In vivo beta-adrenergic stimulation suppresses natural killer activity and compromises resistance to tumor metastasis in rats. J Immunol 160:3251-3258
93. Sloan EK, Priceman SJ, Cox BF, Yu S, Pimentel MA, Tangkanangnukul V, Arevalo JM, Morizono K, Karanikolas BD, Wu L, Sood AK, Cole SW (2010) The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res 70:7042-7052
94. Sood AK, Bhatty R, Kamat AA, Landen CN, Han L, Thaker PH, Li Y, Gershenson DM, Lutgendorf S, Cole SW (2006) Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 12:369-375
95. Souberbielle B, Dalgleish AG (1994) In: Lewis CE, Sullivan CO, Baraclough J (eds) The psychoimmunology of cancer: mind and body in the fight for survival. Oxford University Press, New York
96. Spiegel D, Giese-Davis J (2003) Depression and cancer: mechanisms and disease progression. Biol Psychiatry 54:269-282
97. Tandle A, Libutti SK (2003) Antiangiogenic therapy: targeting vascular endothelial growth factor and its receptors. Clin Adv Hematol Oncol 1:41-48
98. Teunis MA, Kavelaars A, Voest E, Bakker JM, Ellenbroek BA, Cools AR, Heijnen CJ (2002) Reduced tumor growth, experimental metastasis formation, and angiogenesis in rats with a hyperreactive dopaminergic system. FASEB J 16:1465-1467
99. Thaker PH, Han LY, Kamat AA, Arevalo JM, Takahashi R, Lu C, Jennings NB, Armaiz-Pena G, Bankson JA, Ravoori M, Merritt WM, Lin YG, Mangala LS, Kim TJ, Coleman RL, Landen CN, Li Y, Felix E, Sanguino AM, Newman RA, Lloyd M, Gershenson DM, Kundra V, Lopez-Berestein G, Lutgendorf SK, Cole SW, Sood AK (2006) Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med 12:939-944
100. Thaker PH, Lutgendorf SK, Sood AK (2007) The neuroendocrine impact of chronic stress on cancer. Cell Cycle 6:430-433
101. Tilan, J, Kitlinska, J (2010) Sympathetic neurotransmitters and tumor angiogenesis-link between stress and cancer progression. J Oncol 539706. doi: 10.1155/2010/539706
102. Vinci MC, Bellik L, Filippi S, Ledda F, Parenti A (2007) Trophic effects induced by alpha1D-adrenoceptors on endothelial cells are potentiated by hypoxia. Am J Physiol Heart Circ Physiol 293:H2140-H2147
103. von Kleist S, Berling J, Bohle W, Wittekind C (1987) Immunohistological analysis of lymphocyte subpopulations infiltrating breast carcinomas and benign lesions. Int J Cancer 40:18-23
104. Wang PS, Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, Avorn J (2002) Dopamine antagonists and the development of breast cancer. Arch Gen Psychiatry 59:1147-1154
105. Whiteside TL (2006) Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 16:3-15
106. Yang EV, Sood AK, Chen M, Li Y, Eubank TD, Marsh CB, Jewell S, Flavahan NA, Morrison C, Yeh PE, Lemeshow S, Glaser R (2006) Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res 66:10357-10364
107. Yang EV, Kim SJ, Donovan EL, Chen M, Gross AC, Webster Marketon JI, Barsky SH, Glaser R (2009) Norepinephrine upregulates VEGF, IL-8, and IL-6 expression in human melanoma tumor cell lines: implications for stress-related enhancement of tumor progression. Brain Behav Immun 23:267-275
108. Zabaleta J (2012) Multifactorial etiology of gastric cancer. Methods Mol Biol 863:411-435
109. Zitvogel L, Tesniere A, Kroemer G (2006) Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat Rev Immunol 6:715-727